Dual Anti-angiogenic Chemotherapy with Temozolomide and Celecoxib in Selected Patients with Malignant Glioma Not Eligible for Standard Treatment

被引：0

作者：

Kerschbaumer, Johannes ^{[1
]}

Schmidt, Franziska Anna

Grams, Astrid Ellen ^{[2
]}

Nowosielski, Martha ^{[3
]}

Pinggera, Daniel ^{[1
]}

Brawanski, Konstantin Robert ^{[1
]}

Petr, Ondra ^{[1
]}

Thome, Claudius ^{[1
]}

Tuettenberg, Jochen ^{[4
]}

Seiz, Marcel ^{[5
]}

Freyschlag, Christian Franz ^{[1
]}

机构：

[1] Med Univ Innsbruck, Dept Neurosurg, A-6020 Innsbruck, Austria

[2] Med Univ Innsbruck, Dept Neuroradiol, A-6020 Innsbruck, Austria

[3] Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria

[4] Klinikum Idar Oberstein, Dept Neurosurg, Idar Oberstein, Germany

[5] Heidelberg Univ, Univ Med Ctr Mannheim, Dept Neurosurg, Mannheim, Germany

来源：

ANTICANCER RESEARCH | 2015年 / 35卷 / 09期

关键词：

Glioblastoma; dual anti-angiogenic chemotherapy; temozolomide; celecoxib; ENDOTHELIAL GROWTH-FACTOR; GLIOBLASTOMA-MULTIFORME; ANTIANGIOGENIC THERAPY; PHASE-3; TRIAL; RADIOTHERAPY; CYCLOOXYGENASE-2; INHIBITION; TOXICITY; SURVIVAL; CRITERIA;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Due to their high rate of neo-angiogenesis, malignant gliomas may qualify for treatment with anti-angiogenic substances. We report on a series of patients with malignant glioma not eligible for standard postoperative combined radiochemotherapy due to decreased health status. Patients and Methods: A total of nine patients with malignant glioma, postoperatively presenting with a Karnofsky performance score (KPS) below 70, were treated with standalone metronomic low-dose chemotherapy with temozolomide and celecoxib (cyclo-oxygenase-2 inhibitor). Overall survival was defined as the primary end-point and the functional status (KPS) and time to progression as secondary end-points of our analysis. Results: The median KPS after surgery was 60. Treatment achieved a decrease in tumor and edema volume and, more importantly, preserved the functional status defined as the ability to care for self (KPS 70%) until disease progression. No notable side-effects were recorded. Conclusion: In patients with decreased general condition (KPS <70), not eligible for standard treatment, antiangiogenic therapy offers a reasonable alternative approach. Our results indicate prolonged survival and preserved quality of life in comparison to best supportive care.

引用

页码：4955 / 4960

页数：6

共 29 条

[1]

[Anonymous], 1949, EVALUATION CHEMOTHER

[2] Evaluation of peritumoral edema in the delineation of radiotherapy clinical target volumes for glioblastoma [J].

Chang, Eric L. ;

Akyurek, Serap ;

Avalos, Tedde ;

Rebueno, Neal ;

Spicer, Chris ;

Garcia, John ;

Famiglietti, Robin ;

Allen, Pamela K. ;

Chao, K. S. Clifford ;

Mahajan, Anita ;

Woo, Shiao Y. ;

Maor, Moshe H. .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 68 (01) :144-150

[3] Response Assessment Criteria for Glioblastoma: Practical Adaptation and Implementation in Clinical Trials of Antiangiogenic Therapy [J].

Chinot, Olivier L. ;

Macdonald, David R. ;

Abrey, Lauren E. ;

Zahlmann, Gudrun ;

Kerloeguen, Yannick ;

Cloughesy, Timothy F. .

CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2013, 13 (05)

[4] Efficacy and toxicity of CyberKnife re-irradiation and "dose dense" temozolomide for recurrent gliomas [J].

Conti, Alfredo ;

Pontoriero, Antonio ;

Arpa, Donatella ;

Siragusa, Carmelo ;

Tomasello, Chiara ;

Romanelli, Pantaleo ;

Cardali, Salvatore ;

Granata, Francesca ;

De Renzis, Costantino ;

Tomasello, Francesco .

ACTA NEUROCHIRURGICA, 2012, 154 (02) :203-209

[5] Chemotherapy for brain tumors - A new beginning [J].

DeAngelis, LM .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (10) :1036-1038

[6] Cyclooxygenase-2 expression in endometrial cancer: Correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase [J].

Fujiwaki, R ;

Iida, K ;

Kanasaki, H ;

Ozaki, T ;

Hata, K ;

Miyazaki, K .

HUMAN PATHOLOGY, 2002, 33 (02) :213-219

[7] Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A:: Roles of the nuclear factor of activated T cells and cyclooxygenase 2 [J].

Hernández, GL ;

Volpert, OV ;

Iñiguez, MA ;

Lorenzo, E ;

Martínez-Martínez, S ;

Grau, R ;

Fresno, M ;

Redondo, JM .

JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (05) :607-620

[8] Radiotherapy for glioblastoma in the elderly [J].

Keime-Guibert, Florence ;

Chinot, Olivier ;

Taillandier, Luc ;

Cartalat-Carel, Stephanie ;

Frenay, Marc ;

Kantor, Guy ;

Guillamo, Jean-Sebastien ;

Jadaud, Eric ;

Colin, Philippe ;

Bondiau, Pierre-Yves ;

Menei, Philippe ;

Loiseau, Hugues ;

Bernier, Valerie ;

Honnorat, Jerome ;

Barrie, Maryline ;

Mokhtari, Karima ;

Mazeron, Jean-Jacques ;

Bissery, Anne ;

Delattre, Jean-Yves ;

Lacomblez, L. ;

Levy-Soussan, M. ;

Mallet, A. ;

Houssard, C. ;

Delgadillo, D. ;

Poitou, M. ;

Hoang-Xuan, K. ;

Sanson, M. ;

Carpentier, A. F. ;

Laigle-Donadey, F. ;

Taillibert, S. ;

Cornu, P. ;

Omuro, A. ;

Capelle, L. ;

Boch, A. -L. ;

Duffau, H. ;

Simon, J. -M. ;

Medioni, J. ;

Broet, P. ;

Schmitt, A. ;

Garat, E. ;

Mathieu, P. ;

Camille, N. ;

Collin, J. -P. ;

Bailet, B. ;

Ciais, C. ;

Fauchon, F. ;

Lebrun, C. ;

Guesdan, G. ;

Stadelmaier, N. ;

Lombard, I. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (15) :1527-1535

[9]

Kizilarslanoglu MC, 2011, J BUON, V16, P547

[10] Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial [J].

Malmstrom, Annika ;

Gronberg, Bjorn Henning ;

Marosi, Christine ;

Stupp, Roger ;

Frappaz, Didier ;

Schultz, Henrik ;

Abacioglu, Ufuk ;

Tavelin, Bjorn ;

Lhermitte, Benoit ;

Hegi, Monika E. ;

Rosell, Johan ;

Henriksson, Roger .

LANCET ONCOLOGY, 2012, 13 (09) :916-926

← 1 2 3 →